GTS Securities LLC Takes $611,000 Position in Novartis AG $NVS

GTS Securities LLC bought a new position in shares of Novartis AG (NYSE:NVS) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 3,897 shares of the company’s stock, valued at approximately $611,000.

A number of other institutional investors have also made changes to their positions in NVS. Morgan Stanley raised its stake in Novartis by 14.9% in the 4th quarter. Morgan Stanley now owns 8,876,906 shares of the company’s stock valued at $1,223,860,000 after acquiring an additional 1,148,033 shares during the period. Fisher Asset Management LLC boosted its position in Novartis by 3.1% during the fourth quarter. Fisher Asset Management LLC now owns 7,465,850 shares of the company’s stock worth $1,029,317,000 after purchasing an additional 226,484 shares during the period. Bank of America Corp DE increased its holdings in shares of Novartis by 9.1% in the first quarter. Bank of America Corp DE now owns 4,962,794 shares of the company’s stock valued at $758,067,000 after purchasing an additional 413,778 shares during the last quarter. Auto Owners Insurance Co raised its position in shares of Novartis by 13,687.0% in the fourth quarter. Auto Owners Insurance Co now owns 4,628,296 shares of the company’s stock valued at $638,103,000 after purchasing an additional 4,594,726 shares during the period. Finally, Franklin Resources Inc. raised its position in shares of Novartis by 10.3% in the fourth quarter. Franklin Resources Inc. now owns 4,479,307 shares of the company’s stock valued at $617,562,000 after purchasing an additional 419,988 shares during the period. 13.12% of the stock is owned by institutional investors and hedge funds.

Novartis Stock Performance

Shares of NYSE NVS opened at $153.75 on Monday. The company has a debt-to-equity ratio of 0.89, a current ratio of 0.86 and a quick ratio of 0.67. The firm has a market cap of $293.38 billion, a price-to-earnings ratio of 23.19, a P/E/G ratio of 2.64 and a beta of 0.45. The stock’s fifty day moving average price is $155.07 and its two-hundred day moving average price is $153.76. Novartis AG has a one year low of $121.57 and a one year high of $170.46.

Novartis (NYSE:NVS) last posted its earnings results on Tuesday, June 30th. The company reported $2.41 earnings per share for the quarter. The company had revenue of $14.95 billion during the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%. On average, equities analysts forecast that Novartis AG will post 8.84 EPS for the current year.

Analyst Ratings Changes

Several brokerages recently commented on NVS. Citigroup reaffirmed a “buy” rating on shares of Novartis in a report on Wednesday, July 22nd. Weiss Ratings restated a “buy (b)” rating on shares of Novartis in a research report on Friday, July 24th. Seven research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Novartis currently has a consensus rating of “Hold” and a consensus target price of $141.20.

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.